Skip to main content

Idiopathic Thrombocytopenic Purpura

4
Pipeline Programs
7
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
2
1
eltrombopagPhase 4
EltrombopagPhase 3
Eltrombopag oral tabletsPhase 3
Kissei Pharmaceutical
Kissei PharmaceuticalJapan - Matsumoto City
1 program
1
R788Phase 31 trial
Active Trials
NCT04132050Completed34Est. Sep 2023
Eisai
EisaiChina - Liaoning
3 programs
10-mg dose of E5501 2G tabletPHASE_11 trial
BlindedPHASE_21 trial
EltrombopagPHASE_31 trial
Active Trials
NCT01549054Completed28Est. Aug 2012
NCT00625443Completed53Est. Oct 2009
NCT01433978Terminated24Est. Sep 2013
GSK
GSKLONDON, United Kingdom
2 programs
Eltrombopag oral tabletsPHASE_31 trial
eltrombopagPHASE_41 trial
Active Trials
NCT00828750Completed19Est. Feb 2011
NCT00888901Completed30Est. May 2011
Sanofi
SanofiPARIS, France
1 program
GMA161PHASE_11 trial
Active Trials
NCT00244257Terminated10Est. Jul 2008
Grifols
GrifolsNEW YORK, NY
1 program
IGIV3I Grifols 10%PHASE_31 trial
Active Trials
NCT00511147Completed64Est. Apr 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKeltrombopag
Kissei PharmaceuticalR788
EisaiEltrombopag
GSKEltrombopag oral tablets
GrifolsIGIV3I Grifols 10%
EisaiBlinded
Eisai10-mg dose of E5501 2G tablet
SanofiGMA161

Clinical Trials (8)

Total enrollment: 262 patients across 8 trials

NCT00888901GSKeltrombopag

Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag

Start: May 2009Est. completion: May 201130 patients
Phase 4Completed
NCT04132050Kissei PharmaceuticalR788

A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788

Start: Dec 2019Est. completion: Sep 202334 patients
Phase 3Completed
NCT01433978EisaiEltrombopag

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Start: Mar 2012Est. completion: Sep 201324 patients
Phase 3Terminated
NCT00828750GSKEltrombopag oral tablets

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Start: May 2008Est. completion: Feb 201119 patients
Phase 3Completed
NCT00511147GrifolsIGIV3I Grifols 10%

IGIV Study for Chronic ITP Patients Ages 3-70

Start: May 2008Est. completion: Apr 201464 patients
Phase 3Completed
NCT00625443EisaiBlinded

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

Start: May 2007Est. completion: Oct 200953 patients
Phase 2Completed
NCT01549054Eisai10-mg dose of E5501 2G tablet

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

Start: Jan 2012Est. completion: Aug 201228 patients
Phase 1Completed
NCT00244257SanofiGMA161

Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Start: Aug 2005Est. completion: Jul 200810 patients
Phase 1Terminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.